NBIX News and Press, Neurocrine Biosciences Inc. From 06/02/23

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate PR Newswire SAN DIEGO , June 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc...

2023-05-31 05:55:18 ET Summary Gain Therapeutics is a biotechnology company focused on drug development powered by its SEE-Tx™ target identification platform, which identifies and optimizes binding sites on biological targets that have never before been targeted. The compan...

2023-05-24 04:31:45 ET Summary Neurocrine Biosciences shows promising growth, boosted by Ingrezza sales, but struggles with high operational costs. Despite significant revenue growth, the company's reliance on a single product for revenue and inconsistent EPS growth raises investo...

2023-05-19 11:27:29 ET BofA Securities has initiated Xencor ( NASDAQ: XNCR ) with a buy highlighting its pipeline of protein therapeutics for cancer and inflammatory diseases. The firm has a $42 price target (~61% upside based on Thursday's close) in Friday morning trading. ...

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology PR Newswire - Statistically Significant Improvement in Chorea Associated with ...

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual Congress PR Ne...

Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023 PR Newswire Post Hoc Analyses of Phase 2 Study of Crinecerfont in Adults with CAH Demonstrate Androgen Reduction Across a Broad Range of Glucocorticoid Doses ...

2023-05-03 12:02:08 ET Neurocrine Biosciences, Inc. (NBIX) Q1 2023 Earnings Conference Call May 3, 2023 08:00 AM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - C...

2023-05-03 07:42:54 ET Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q1 Non-GAAP EPS of -$0.51. Revenue of $420.4M (+35.4% Y/Y) beats by $11.33M . First Quarter INGREZZA Net Product Sales Highlights: INGREZZA first quarter 2023 net product sales we...

Neurocrine Biosciences Reports First Quarter 2023 Financial Results PR Newswire INGREZZA ® (valbenazine) First Quarter Net Product Sales of $410 Million INGREZZA ® (valbenazine) 2023 Net Product Sales Guidance Reiterated at $1.67 - $1....